Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.
about
A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State.Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosisPopulation-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.
P2860
Q33812455-B2F2F92E-F066-4AAF-A3CE-F574F76528CFQ36337329-E4FD7353-CEAC-48A2-9838-00F81AA0D24BQ37120038-4E03B020-9212-4441-9469-434DA4EB4762Q37133281-922116A1-5B1D-4C0D-A6E2-EC16830B02A9Q37270722-A7B6233B-50BE-43B9-B57A-ACE088B39381Q37739640-AF3F55E0-BCE5-4BEF-918E-A3978C4B5A46Q38739933-FB9EDDF7-E31B-414D-B2EA-2B9005935D50Q39398946-C32E040C-1B09-4803-8621-6BBD2A8B77FAQ40282057-DA94BA14-6B06-499B-98DA-1AEF2B7E211DQ41701192-AD6299BD-7B4D-4A14-8813-33CDBF6AC049Q46765284-D1403DC4-C96E-4FAF-B797-BE3816F7E952Q50223757-9BDF0091-3598-4BDE-AFD0-133619434061Q53698791-97528BF7-C6B4-4FE0-8EE5-99B22FB0662A
P2860
Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@ast
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@en
type
label
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@ast
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@en
prefLabel
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@ast
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@en
P2093
P2860
P50
P356
P1476
Mycobacterium tuberculosis pnc ...... ograms per Milliliter in MGIT.
@en
P2093
Alexandra Mercante
Frik A Sirgel
Glenn Morlock
James E Posey
Kelsey Hughes
Kris Birkness
Melisa Willby
Paul D van Helden
P2860
P304
P356
10.1128/JCM.01001-15
P407
P577
2015-08-19T00:00:00Z